MX2022001377A - Composiciones de ester de forbol y su uso en metodos para tatar o reducir la duración de la citopenia. - Google Patents

Composiciones de ester de forbol y su uso en metodos para tatar o reducir la duración de la citopenia.

Info

Publication number
MX2022001377A
MX2022001377A MX2022001377A MX2022001377A MX2022001377A MX 2022001377 A MX2022001377 A MX 2022001377A MX 2022001377 A MX2022001377 A MX 2022001377A MX 2022001377 A MX2022001377 A MX 2022001377A MX 2022001377 A MX2022001377 A MX 2022001377A
Authority
MX
Mexico
Prior art keywords
cytopenia
methods
duration
phorbol ester
treating
Prior art date
Application number
MX2022001377A
Other languages
English (en)
Inventor
Zheng Tao Han
Original Assignee
Biosuccess Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosuccess Biotech Co Ltd filed Critical Biosuccess Biotech Co Ltd
Publication of MX2022001377A publication Critical patent/MX2022001377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan un éster de forbol o un derivado de un éster de forbol en combinación con G-CSF o en combinación con EPO, y composiciones que contienen el mismo, y su uso en métodos para el tratamiento o reducción de la duración de la citopenia, tal como neutropenia, trombocitopenia, y/o anemia, en sujetos mamíferos.
MX2022001377A 2014-11-03 2017-04-26 Composiciones de ester de forbol y su uso en metodos para tatar o reducir la duración de la citopenia. MX2022001377A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462074133P 2014-11-03 2014-11-03

Publications (1)

Publication Number Publication Date
MX2022001377A true MX2022001377A (es) 2022-04-01

Family

ID=54479028

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005499A MX2017005499A (es) 2014-11-03 2015-11-03 Composiciones de ester de forbol y metodos de uso para tratar o reducir la duracion de la citopenia.
MX2022001377A MX2022001377A (es) 2014-11-03 2017-04-26 Composiciones de ester de forbol y su uso en metodos para tatar o reducir la duración de la citopenia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017005499A MX2017005499A (es) 2014-11-03 2015-11-03 Composiciones de ester de forbol y metodos de uso para tratar o reducir la duracion de la citopenia.

Country Status (18)

Country Link
US (3) US11260041B2 (es)
EP (1) EP3215177B1 (es)
JP (1) JP6755865B2 (es)
KR (1) KR102527457B1 (es)
CN (2) CN107206053B (es)
AU (1) AU2015343375B2 (es)
BR (1) BR112017009237A2 (es)
CA (1) CA2965848A1 (es)
HK (1) HK1244203A1 (es)
IL (2) IL285900B2 (es)
MA (1) MA40904A (es)
MX (2) MX2017005499A (es)
MY (1) MY185869A (es)
PH (1) PH12017500814A1 (es)
RU (2) RU2020125187A (es)
SG (3) SG11201703530TA (es)
TW (1) TWI725947B (es)
WO (1) WO2016073416A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
CN108653265A (zh) * 2018-04-26 2018-10-16 五邑大学 一种复合抗癌药物
KR102178075B1 (ko) * 2020-07-31 2020-11-13 (주)쓰리에이씨 마스크 수명 인디케이터 및 이를 포함하는 마스크

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
AU5277902A (en) * 1995-03-03 2002-08-15 Trustees Of Boston University Compositions for the treatment of blood disorders
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US7407026B2 (en) * 2000-10-11 2008-08-05 Ford Global Technologies, Llc Control system for a hybrid electric vehicle to anticipate the need for a mode change
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
MY186986A (en) * 2007-01-31 2021-08-26 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters
US9636317B2 (en) * 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US11564901B2 (en) * 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
KR20110132327A (ko) * 2009-01-16 2011-12-07 테바 파마슈티컬 인더스트리즈 리미티드 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
KR102102640B1 (ko) 2012-01-18 2020-06-01 바이오석세스 바이오텍 컴퍼니 리미티드 뇌졸중 치료용 포르볼 에스테르들의 조성물

Also Published As

Publication number Publication date
US20220133675A1 (en) 2022-05-05
JP2017534632A (ja) 2017-11-24
TW201630597A (zh) 2016-09-01
BR112017009237A2 (pt) 2017-12-26
IL251937B (en) 2021-09-30
KR20170072347A (ko) 2017-06-26
SG11201703530TA (en) 2017-05-30
CN107206053A (zh) 2017-09-26
CN107206053B (zh) 2022-06-07
JP6755865B2 (ja) 2020-09-16
RU2017119183A (ru) 2018-12-05
CN114887038A (zh) 2022-08-12
US20160120836A1 (en) 2016-05-05
HK1244203A1 (zh) 2018-08-03
EP3215177B1 (en) 2022-05-11
PH12017500814A1 (en) 2017-10-02
RU2730998C2 (ru) 2020-08-26
MX2017005499A (es) 2017-08-04
SG10201903942UA (en) 2019-05-30
RU2020125187A (ru) 2020-08-27
SG10201911605TA (en) 2020-01-30
IL285900A (en) 2021-09-30
MY185869A (en) 2021-06-14
IL285900B (en) 2022-11-01
CA2965848A1 (en) 2016-05-12
US11260041B2 (en) 2022-03-01
NZ731599A (en) 2021-04-30
WO2016073416A1 (en) 2016-05-12
AU2015343375A1 (en) 2017-05-25
RU2017119183A3 (es) 2019-05-16
TWI725947B (zh) 2021-05-01
US20170224648A1 (en) 2017-08-10
EP3215177A1 (en) 2017-09-13
KR102527457B1 (ko) 2023-04-28
IL285900B2 (en) 2023-03-01
IL251937A0 (en) 2017-06-29
AU2015343375B2 (en) 2021-07-01
MA40904A (fr) 2017-09-12

Similar Documents

Publication Publication Date Title
PH12016501512B1 (en) Treatment for resistant acne
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
EP3665181A4 (en) COMPOSITIONS AND PROCEDURES FOR DECOLONIZATION OF ANTIBIOTIC-RESISTANT BACTERIA IN THE INTESTINAL
EP3137605A4 (en) Compositions and methods for modulating angiopoietin-like 3 expression
WO2015117081A3 (en) Methods and compositions for treatment of a beta thalessemia
MX2017002852A (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
MX367326B (es) Composiciones antimicrobianas.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2022001377A (es) Composiciones de ester de forbol y su uso en metodos para tatar o reducir la duración de la citopenia.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
EA030204B8 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
MY193650A (en) Extracellular matrix compositions
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
EP3634431A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B
ZA201706915B (en) Methods and compositions for the treatment of cellulosic biomass and products produced thereby
EP3532644A4 (en) METHODS AND COMPOSITIONS FOR THE PRESERVATION OF BACTERIA
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
EP3368034A4 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF HEAD NECK CARCINOMA
EP3391893A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF LEUKEMIA AND MANUFACTURING METHOD THEREFOR
WO2015191449A3 (en) Personal care products containing microalgae or extracts thereof
EP3107533A4 (en) Compositions and methods for treating neutropenia